You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 19, 2018

Asia Business Law Journal Names Ten Tilleke & Gibbins Lawyers among Thailand’s Top 100

Asia Business Law Journal  recently published a complete list of the top 100 lawyers in Thailand— the result of extensive, in-depth market research including nominations and feedback from in-house counsel from around the world. Tilleke & Gibbins is proud to announce that the following ten professionals from our Bangkok office have been included in the list:

With ten entries Tilleke & Gibbins has the highest number of named lawyers from a single firm in Thailand. To see the complete list of recognized lawyers, please visit Asia Business Law Journal’s  website.

RELATED INSIGHTS​ 

June 14, 2012
A report in the June issue of Asian Legal Business explores the growth of renewable energy production in Southeast Asia. The story highlights the obstacles that the region faces, including high energy costs, an underdeveloped infrastructure, and a volatile regulatory environment. Despite these, the report provides affirmation of the clean energy revolution that has started brewing in Southeast Asia, particularly in the production of solar, wind, and geothermal energy.
May 29, 2012
The ASEAN Economic Community (AEC), which will come into effect in 2015, will integrate the region’s economies and create a single market of 600 million consumers. All industries are bracing for this change, but the competitive landscape is transforming even more quickly in the healthcare sector. Regional harmonization has already commenced for the cosmetics industry, while further integration is imminent for other industries and products, such as medical devices.
May 29, 2012
The Thai pharmaceutical industry is characterized by its expanding yet challenging landscape. Amidst growing medical tourism and strong R&D centers in the Asia Pacific region, issues related to patent protection, counterfeit drugs, and innovation recognition are increasingly imperative for pharmaceutical companies.